Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements

Clinical Cancer Research

Volumn 8, Issue 7, 2002, Pages 2336-2344

  Huarte, Eduardo ^a   Sarobe, Pablo ^a   Lu, Jun ^b   Casares, Noelia ^a   Lasarte, Juan José ^a   Dotor, Javier ^a   Ruiz, Marta ^a   Prieto, Jesús ^a   Celis, Esteban ^b   Borrás Cuesta, Francisco ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; EPITOPE; HLA A2 ANTIGEN; SYNTHETIC PEPTIDE; TYROSINE; CANCER VACCINE; PEPTIDE FRAGMENT;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; CELLULAR IMMUNITY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; TRANSGENIC MOUSE; ANIMAL; COMPARATIVE STUDY; CYTOTOXICITY; DENDRITIC CELL; IMMUNOLOGY; IN VITRO STUDY; PROTEIN BINDING; SYNTHESIS; VACCINATION;

ANIMAL; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; COMPARATIVE STUDY; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; EPITOPES; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMAN; IN VITRO; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PROTEIN BINDING; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; T-LYMPHOCYTES, CYTOTOXIC; TYROSINE; VACCINATION; ANIMALS; HUMANS;

EID: 0035992407     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Antigen recognition by class I-restricted T lymphocytes
2. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
3. Tumor antigens recognized by T lymphocytes
4. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein
5. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines
6. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines
7. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine
8. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins
9. Human tumor antigens recognized by T cells
10. Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and-A33
11. The multi-epitope approach for immunotherapy for cancer: Identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors
12. Identification of HLA-B27-restricted cytotoxic T lymphocyte epitope from carcinoembryonic antigen
13. Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives
14. Modification of the cytotoxic T cell repertoire in neonatal tolerance. Evidence for preferential survival of cells with low avidity for tolerogen
15. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues
16. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope
17. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues
18. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL
19. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen
20. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide
21. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope
22. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
23. gp100/pmel 17 is a murine tumor rejection antigen: Induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand
24. In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells
25. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex
26. Identification of peptide sequences that potentially trigger HLA-A2.-restricted cytotoxic T lymphocytes
27. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions
28. Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection
29. Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood
30. A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: Implication in the identification of cryptic tumor epitopes
31. Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-envelope protein to human cytotoxic T lymphocytes
32. Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region
33. The antigenic identity of peptide-MHC complexes: A comparison of the conformations of five viral peptides presented by HLA-A2
34. Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach
35. A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: Implication for more effective immunotherapy